Navigation Links
Respironics to Webcast Fiscal 2008 First Quarter Conference Call

MURRYSVILLE, Penn., Oct. 17 /PRNewswire-FirstCall/ -- Respironics, Inc. (Nasdaq: RESP), a recognized resource in the medical device market, announced today that it intends to release its first quarter results for the period ending September 30, 2007 on Thursday October 25, 2007. In conjunction with this release and to review the Company's results and business outlook, Respironics will host a conference call that will be broadcast simultaneously live over the Internet.

Individuals wishing to participate on the Webcast, to be held at 8:30 a.m. EST on Thursday October 25, 2007, can access the event at the Company's web site at Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast. The online archive of the broadcast will be available within 2 hours of the live call and will be available for 30 days.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and healthcare providers. Respironics markets its products in 141 countries and employs over 5,100 associates worldwide. Further information can be found on the Company's Web site:


This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company's products and programs; the results of clinical trials; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major natural disaster, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company's stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

(C) 2007 Respironics, Inc. and its affiliates. All rights reserved.

SOURCE Respironics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. BoneCare doubles options and profits as fiscal year closes
3. Sonic Foundry Reports Fiscal 2003 Results
4. The Genesis of Gendicine: The Story Behind the First Gene Therapy
5. Midwest life science stocks sizzle in a tepid first quarter
6. Morgridge Institute for Research seeks first CEO
7. Sonic Foundry reports first cash-positive quarter
8. Angel investors commit $12.7B in first half of `06
9. Aurora team implants Wisconsins first total artificial heart
10. First half of 2006 roundup: Big Pharma trumps biotech
11. GE announces first installation of Discovery VCT
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
Breaking Biology News(10 mins):